A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma

Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin wer...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cell reports. Medicine Ročník 6; číslo 6; s. 102165
Hlavní autoři:	Lopez, Juanita Suzanne, Haefliger, Simon, Plummer, Ruth, Clement, Paul M., Jeffry Evans, Thomas R., Läubli, Heinz, Roth, Patrick, Kristeleit, Rebecca, Brazil, Lucy, Tabatabai, Ghazaleh, Wick, Antje, Wunderlich, Benjamin, Beebe, Kirk, Eisner, Joel Robert, Lane, Heidi, Engelhardt, Marc, Kaindl, Thomas, Hau, Peter, Hundsberger, Thomas, Steinbach, Joachim
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 17.06.2025 Elsevier
Témata:	Administration, Oral Adult Advanced Basic Science Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use astrocytoma Biomarkers, Tumor - metabolism Brain Neoplasms - drug therapy Brain Neoplasms - pathology Dose-Response Relationship, Drug Female glioblastoma Glioblastoma - drug therapy Glioblastoma - metabolism Glioblastoma - pathology glioma Glioma - drug therapy Glioma - metabolism Glioma - pathology Humans lisavanbulin Male Middle Aged Neoplasm Grading glioma glioblastoma lisavanbulin astrocytoma
ISSN:	2666-3791, 2666-3791
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!